pubmed.ncbi.nlm.nih.gov

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin) - PubMed

  • ️Tue Jan 01 2013

Randomized Controlled Trial

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Deanna L Kelly et al. BMC Psychiatry. 2013.

Abstract

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Change in Prolactin Levels over 8 weeks in a Double Blind Trial: Aripiprazole vs. Placebo.

Similar articles

Cited by

References

    1. Beumont PJ. et al.The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. J Psychiatry. 1974;124:413–419. doi: 10.1192/bjp.124.5.413. - DOI - PubMed
    1. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291–2314. doi: 10.2165/00003495-200464200-00003. - DOI - PubMed
    1. Hellewell JSE, Cantillon M. Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy. Eur Neuropsychopharmacol. 1998;8:S248.
    1. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21(7):768–773. - PubMed
    1. Buchanan RW. et al.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. doi: 10.1093/schbul/sbp116. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances